Drugs / Meningococcal ACWY
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02868970 | Feb 2017 → Jul 2021 | — | Canadian Immunization Research Network | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-11-27 | GlaxoSmithKline | Regulatory GSK’s fully liquid Menveo meningococcal vaccine approved by European Commission gsk.com ↗
GSK plc (LSE/NYSE: GSK) today announced that the European Commission (EC) has approved a single-vial, fully liquid presentation of Menveo (Meningococcal Group A, C, W-135 and Y conjugate vaccine, MenACWY vaccine) to help protect against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W and Y. |
| 2024-09-24 | GlaxoSmithKline | Regulatory GSK’s Menveo meningococcal vaccine in new single-vial, fully liquid presentation receives positive European CHMP opinion gsk.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-27 | GlaxoSmithKline | GSK’s fully liquid Menveo meningococcal vaccine approved by European Commission gsk.com ↗ |
| 2024-09-24 | GlaxoSmithKline | GSK’s Menveo meningococcal vaccine in new single-vial, fully liquid presentation receives positive European CHMP opinion gsk.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningococcal ACWY | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02868970 ↗ |
| Modality | Vaccine | “Meningococcal ACWY vaccine is indicated for active immunization of individuals up to 55 years of age against invasive meningococcal diseases caused by Neisseria meningitides...” NCT02868970 ↗ |